Modulation of Cell Signaling Networks after CTLA4 Blockade in Patients with Metastatic Melanoma

por Comin-Anduix, Begoña, Sazegar, Hooman, Chodon, Thinle, Matsunaga, Douglas, Jalil, Jason, von Euw, Erika, Escuin-Ordinas, Helena, Balderas, Robert, Chmielowski, Bartosz, Gomez-Navarro, Jesus, Koya, Richard C., Ribas, Antoni
Publicado 2010

Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations

por Niehr, Franziska, von Euw, Erika, Attar, Narsis, Guo, Deliang, Matsunaga, Doug, Sazegar, Hooman, Ng, Charles, Glaspy, John A, Recio, Juan A, Lo, Roger S, Mischel, Paul S, Comin-Anduix, Begonya, Ribas, Antoni
Publicado 2011

Natural Killer T Cells in Advanced Melanoma Patients Treated with Tremelimumab

por Ibarrondo, F. Javier, Yang, Otto O., Chodon, Thinle, Avramis, Earl, Lee, Yohan, Sazegar, Hooman, Jalil, Jason, Chmielowski, Bartosz, Koya, Richard C., Schmid, Ingrid, Gomez-Navarro, Jesus, Jamieson, Beth D., Ribas, Antoni, Comin-Anduix, Begoña
Publicado 2013

Differential sensitivity of melanoma cell lines with BRAF(V600E )mutation to the specific Raf inhibitor PLX4032

por Søndergaard, Jonas N, Nazarian, Ramin, Wang, Qi, Guo, Deliang, Hsueh, Teli, Mok, Stephen, Sazegar, Hooman, MacConaill, Laura E, Barretina, Jordi G, Kehoe, Sarah M, Attar, Narsis, von Euw, Erika, Zuckerman, Jonathan E, Chmielowski, Bartosz, Comin-Anduix, Begoña, Koya, Richard C, Mischel, Paul S, Lo, Roger S, Ribas, Antoni
Publicado 2010